Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    evp-6124, schizophrenia
Show Display Options
Rank Status Study
1 Recruiting Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Interventions: Drug: EVP-6124;   Drug: Placebo
2 Recruiting Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Interventions: Drug: EVP-6124;   Drug: Placebo
3 Recruiting A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Intervention: Drug: EVP-6124
4 Completed Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
Conditions: Schizophrenia;   Central Nervous System Diseases;   Cognition
Interventions: Drug: EVP-6124;   Drug: Placebo
5 Completed
Has Results
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Central Nervous System Diseases
Interventions: Drug: EVP-6124 (0.3 mg/day);   Drug: EVP-6124 (1.0 mg/day);   Drug: Placebo;   Drug: Antipsychotic therapy

Indicates status has not been verified in more than two years